Aurobindo Pharma said the Central Drugs Standard Control Organization (CDSCO) has granted marketing authorization under Form CT 23 for the bevacizumab biosimilar for metastatic carcinoma of the colon or rectum.
Aurobindo Pharma said the Central Drugs Standard Control Organization (CDSCO) has granted marketing authorization under Form CT 23 for the bevacizumab biosimilar for metastatic carcinoma of the colon or rectum.